Neutrophil-to-lymphocyte ratio as a prognostic factor for survival in patients with colorectal liver metastases: A systematic review

Table 2 Survival and disease characteristics

Ref.	Median Survival	5-year OS	5-year DFS	Extrahepatic Disease	Primary Tumor	Chemotherapy
Erstad et al[13]	3.1 yr, NLR > 5; 6.3 yr NLR < 5	28.7%, NLR > 5; 59.6%, NLR < 5	NS	Νο	Previous resection of rectum or colon	Neoadjuvant
Halazun et al[14]	NS	22%, NLR > 5; 43%, NLR < 5	12%, NLR > 5; 42%, NLR < 5	No disseminated or unresectable EHD	Previously resected	Neoadjuvant
Kishi et al[15]	34 mo, NLR > 5; 45 mo, NLR < 5	26%, NLR > 5; 36%, NLR < 5	NS	No	Previously resected	Neoadjuvant, n = 200; Without resection, n = 90
Neal et al[16]	27.8 mo, NLR > 5; 39.8 mo, NLR < 5	18.5% NLR > 5; 30.6% NLR < 5	22.3%, NLR > 5; 35.2%, NLR < 52	NS	Rectum n = 149, Colon n = 153	Adjuvant, n = 126
Hand et al[17]	59 mo	Chemotherapy group, 50.8%; No chemotherapy group, 42.5%	NS	NS	No	Neoadjuvant, n = 202
Peng et al[18]	NS	18.8%, NLR > 4.63; 46.7%, NLR < 4.63	NS	No	58% colon, 42% rectum	Neoadjuvant, n = 59
Kim et al[19]	NS	NS	NS	No	NS	Neoadjuvant, n = 24
Mao et al[20]	31.1 mo NLR > 2.3 43.1 mo NLR < 2.3	NS	NS	No	Colon n = 104	Neoadjuvant, n = 183
Neofytou et al[21]	55 mo, NLR > 2.4; Not reached, NLR < 2.4	42%, NLR > 2.4; 69%, NLR < 2.4	Total 27%. 14%, NLR > 2.4; 40%, NLR < 2.4	Νο	Resection prior to hepatectomy in 81%	Neoadjuvant
Giakoustidis et al[22]	75 mo	51%, NLR > 2.5; 74% NLR < 2.5	NS	No	Synchronous resection, n = 26; ‘liver first’, n = 7	Neoadjuvant, n = 169
Dupré et al[23]	50.3, NLR < 2.5; 38.4, NLR > 2.5; 44.8, NLR < 7.26; 25.4, NLR > 7.26	NS	11.6, NLR < 2.5; 9.7, NLR > 2.5; 10.3, NLR < 7.26; 6.3, NLR > 7.261	Resectable EHD in 36 patients	Synchronous, n = 169; Right colon, n = 73; Left colon, n = 126; Rectum, n = 142; Multiple, n = 2	Neoadjuvant, n = 198
Hamada et al[24]	NS	NS	NS	Yes, n = 5	NS	Adjuvant, n = 15
Zeman et al[25]	Resection group, 56 mo	46.6%, resection group; 9.5%, RFA group	30.5%, resection group, 21 mo median	No	Rectum n = 60, colon n = 70	Adjuvant, n = 25

¹PFS: Progression-Free Survival.

²CSS: Cancer-Specific Survival.

OS: Overall survival; DFS: Disease-free survival; NLR: Neutrophil to lymphocyte ratio; NS: Not stated; EHD: Extra-hepatic disease.